Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCN4 | Q9Y3Q4 | 5/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.98 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.98 |
| ▸ | DRD3 | P35462 | 2/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.64 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.64 |
| ▸ | HTR1A | P08908 | 1/20 | 0.64 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.64 |
| ▸ | SMPD1 | P17405 | 6/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zatebradine SCHEMBL4242335 | 1.00 | HCN4 (1.00) | HCN4MAPTCYP3A4ALOX15DRD3 | |
| Zatebradine SCHEMBL29977754 | 1.00 | HCN4 (1.00) | HCN4MAPTCYP3A4ALOX15DRD3 | |
| Zatebradine SCHEMBL10978655 | 0.99 | CYP3A4 (1.00) | HCN4MAPTCYP3A4ALOX15DRD3 | |
| Zatebradine SCHEMBL29465193 | 0.99 | CYP3A4 (1.00) | HCN4MAPTCYP3A4ALOX15DRD3 | |
| Zatebradine SCHEMBL1588590 | 0.99 | CYP3A4 (1.00) | HCN4MAPTCYP3A4ALOX15DRD3 | |
| Zatebradine SCHEMBL1650770 | 0.98 | HCN4 (0.96) | HCN4MAPTCYP3A4ALOX15DRD3 | |
| Hydrochloric Acid SCHEMBL11094976 | 0.96 | CYP3A4 (0.94) | HCN4MAPTCYP3A4ALOX15DRD3 | |
| SCHEMBL10598399 | 0.96 | HCN4 (0.92) | HCN4MAPTCYP3A4ALOX15DRD3 | |
| SCHEMBL11088082 | 0.95 | HCN4 (0.91) | HCN4MAPTCYP3A4ALOX15DRD3 | |
| Hydrochloric Acid SCHEMBL10598067 | 0.95 | CYP3A4 (0.92) | HCN4MAPTCYP3A4ALOX15DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 711 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110073213-B | Method, device and kit for determining cardiac conduction | 罗斯托克大学 | 2024-03-29 | — | — | CN | claimed |
| US-20230270693-A1 | Molecular Targets for Modulation of Dissociative and Associative States | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2023-08-31 | — | — | US | claimed |
| EP-4087469-A1 | DEVICES AND METHODS FOR TREATING CANCER AND CARDIAC WASTING | Nazzano Devices Limited (IE) | 2022-11-16 | — | — | EP | claimed |
| US-20220347150-A1 | TASIMELTEON USE IN TREATING SLEEP ABERRATIONS | VANDA PHARMACEUTICALS INC. | 2022-11-03 | — | — | US | claimed |
| CN-114641284-A | Application of tasimelteon in treatment of abnormal sleep | 万带兰制药公司 | 2022-06-17 | — | — | CN | claimed |
| EP-3989964-A1 | TASIMELTEON USE IN TREATING SLEEP ABERRATIONS | Vanda Pharmaceuticals Inc. (US) | 2022-05-04 | — | — | EP | claimed |
| WO-2022035773-A1 | MOLECULAR TARGETS FOR MODULATION OF DISSOCIATIVE AND ASSOCIATIVE STATES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-02-17 | — | — | WO | claimed |
| EP-3810184-A2 | METHODS OF TREATING OR INHIBITING ONSET OF HUNTINGTON'S DISEASE | University of Rochester (US) | 2021-04-28 | — | — | EP | claimed |
| CN-112654366-A | Methods of treating or inhibiting the onset of huntington's disease | 罗切斯特大学 | 2021-04-13 | — | — | CN | claimed |
| WO-2021003086-A1 | TASIMELTEON USE IN TREATING SLEEP ABERRATIONS | VANDA PHARMACEUTICALS INC. (US) | 2021-01-07 | — | — | WO | claimed |
| EP-1276476-A2 | USE OF BRADYCARDIAC SUBSTANCES IN THE TREATMENT OF MYOCARDIAL DISEASES ASSOCIATED WITH HYPERTROPHY AND NOVEL MEDICAMENT COMBINATIONS | Boehringer Ingelheim Pharma KG (DE) | 2003-01-22 | — | — | EP | claimed |
| WO-2002100328-A2 | TREATING PAIN BY TARGETING HYPERPOLARIZATION-ACTIVATED, CYCLIC NUCLEOTIDE-GATED CHANNELS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-12-19 | — | — | WO | claimed |
| WO-2002100408-A2 | TREATING NEUROPATHIC/INFLAMMATORY PAIN BY TARGETING A COMPOSITION (E.G. ZD7288) TO HCN PACEMAKER CHANNELS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-12-19 | — | — | WO | claimed |
| WO-2001078699-A2 | USE OF BRADYCARDIAC SUBSTANCES IN THE TREATMENT OF MYOCARDIAL DISEASES ASSOCIATED WITH HYPERTROPHY AND NOVEL MEDICAMENT COMBINATIONS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-10-25 | — | — | WO | claimed |
| EP-0904097-A2 | COMBINATIONS OF VASOPRESSIN AND ADRENERGIC AGENTS FOR THE TREATMENT OF CARDIAC ARREST | Lurie, Keith G. (US) | 1999-03-31 | — | — | EP | claimed |
| WO-1997036609-A2 | COMBINATIONS OF VASOPRESSIN AND ADRENERGIC AGENTS FOR THE TREATMENT OF CARDIAC ARREST | LURIE KEITH G (US) | 1997-10-09 | — | — | WO | claimed |
| US-5643915-A | ANTIINFLAMMATORY AGENTS | ANDRULIS PHARMACEUTICALS CORP. (US) | 1997-07-01 | — | — | US | claimed |
| US-5595987-A | CARDIOVASCULAR DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1997-01-21 | — | — | US | claimed |
| EP-0065229-B1 | BENZAZEPINES, PROCESS FOR THEIR PREPARATION AND THEIR APPLICATION AS PHARMACEUTICAL PREPARATIONS | Dr. Karl Thomae GmbH (DE) | 1985-08-07 | — | — | EP | claimed |
| US-4490369-A | HYPOTENSIVE, BRRADYCARDIAL | DR. KARL THOMAE GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1984-12-25 | — | — | US | claimed |